BioNTech SE (BNTX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $96.06 (-2.64%), Market cap $23.60B, 52-week low–high $83.89 ~ $119.34.
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non
Financial statements, price targets, institutional (13F) holdings and related news for BioNTech SE are updated in real time on BlackAll Trade.
BioNTech SE trades at $96.06 (-2.64%). Real-time quotes and charts are available on BlackAll Trade.
BioNTech SE has a market cap of about $23.60B.
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2